TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3510820

Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol (1.30 mg six times a day)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (plasma levels of 10-15 micrograms/ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combined drug therapy (metaproterenol + theophylline)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metaproterenol-placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Theophylline-placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo-placebo
Number of subjects: 10
Study: 28894067

Group type: EXPERIMENTAL
Intervention: Empowerment Education Program (EEP) for kidney transplant patients, conducted weekly for six weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 53
Study: 27039153

Group type: COMPARATOR
Intervention: Conventional CPR (CVC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chest Compression only CPR (CCC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SL (shown the approximate location on the lower half of the sternum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2F (2 finger-breadth proximal from xiphoid process)
Number of subjects: 0
Study: 24576513

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN) added to usual care
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 300
Study: 22321661

Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 1119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1119
Study: 19497171

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 25
Study: 17923611

Group type: COMPARATOR
Intervention: Absent hippocampal atrophy
Number of subjects: 323

Group type: COMPARATOR
Intervention: Moderate hippocampal atrophy
Number of subjects: 323

Group type: COMPARATOR
Intervention: Severe hippocampal atrophy
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: APOE epsilon 4 allele
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: General cognition
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Baseline hippocampal atrophy
Number of subjects: 323
Study: 15764050

Group type: EXPERIMENTAL
Intervention: Ultrasound rated at 1 W/cm(2) with compressive therapy (Group A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ultrasound rated at 0.5 W/cm(2) with compressive therapy (Group B)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Topical pharmacological treatment (Group C)
Number of subjects: 65
Study: 12198045

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate, 2.48 mmol, injected 20 s before propofol administration
Number of subjects: 0
Study: 10536243

Group type: EXPERIMENTAL
Intervention: Witepsol H15 (fast drug-releasing suppository)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Witepsol W35 (slow drug-releasing suppository)
Number of subjects: 8
Study: 7763215

Group type: EXPERIMENTAL
Intervention: Isolutrol 0.15 g/100 mL (Ketsugo)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 5% benzoyl peroxide lotion
Number of subjects: 70
Study: 1689807

Group type: EXPERIMENTAL
Intervention: ondansetron (0.15 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: placebo (normal saline)
Number of subjects: 28
Study: 6106884

Group type: EXPERIMENTAL
Intervention: Cardiotensin (100mg bupranolol, 10mg bemetizide, 20mg triamterene)
Number of subjects: 30
Study: 31193584

Group type: EXPERIMENTAL
Intervention: Self-help intervention with chat support
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Self-help intervention without chat support
Number of subjects: 311

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 311
Study: 28714741

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 34
Study: 27565521

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes (PROs) and Socioeconomic Status (SES) before HCT
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Pretransplantation Cancer and Treatment Distress (CTXD)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Lower attained education
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Lower income
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Lack of employment before transplantation
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Unmarried status
Number of subjects: 646
Study: 24474520

Group type: EXPERIMENTAL
Intervention: Auscultation technique using a standard stethoscope over the catheter insertion site after injecting 2 mL of NaCl 0.9% solution.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subcutaneous injections (control group) in the opposite arm.
Number of subjects: 20
Study: 23346249

Group type: EXPERIMENTAL
Intervention: Continued treatment for another 7 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: No treatment for the next 7 days
Number of subjects: 30
Study: 20922911

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg/daily)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17327324

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Subcutaneous insulin
Number of subjects: 580
Study: 15654523

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and plication (RAP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy (MM)
Number of subjects: 60
Study: 11481363

Group type: EXPERIMENTAL
Intervention: Women with breast cancer considering participation in clinical trials (33%)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Knowledge about randomized trials
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Desire for an active role in decision-making
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Positive aspects of clinical trials
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Negative aspects of clinical trials
Number of subjects: 545
Study: 9442783

Group type: EXPERIMENTAL
Intervention: Topical dorzolamide (3 times daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral acetazolamide 250 mg (single administration)
Number of subjects: 16
Study: 7734461

Group type: EXPERIMENTAL
Intervention: Usual care plus frequent urine testing and acupuncture treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care plus frequent urine testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 2556725

Group type: EXPERIMENTAL
Intervention: ACTH 4‐10 (1 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HOE 427 (200 micrograms)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: HOE 427 (60 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 4367686

Group type: EXPERIMENTAL
Intervention: 3,4-dihydro-1-isoquinolineacetamide hydrochloride (DIQA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29189579

Group type: EXPERIMENTAL
Intervention: Whole-body exergaming (WBE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 25
Study: 28676252

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 25245776

Group type: EXPERIMENTAL
Intervention: Scrambler therapy for up to ten daily 30‐min sessions
Number of subjects: 37
Study: 23218575

Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated bioactive stents (BAS)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 425
Study: 21534651

Group type: EXPERIMENTAL
Intervention: Therapist-guided exposure in situ (T+)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Therapist-prescribed exposure in situ (T-)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 369
Study: 19950325

Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (PRT) for 24 weeks, twice weekly
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (range of movement home exercise)
Number of subjects: 28
Study: 16850327

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rabeprazole 20 mg
Number of subjects: 24
Study: 15478851

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor treatment for 4 weeks
Number of subjects: 50
Study: 11532418

Group type: EXPERIMENTAL
Intervention: Longo stapled circumferential mucosectomy (LSCM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hospital Leopold Bellan (HLB) hemorrhoidectomy
Number of subjects: 80
Study: 9407268

Group type: EXPERIMENTAL
Intervention: Relevant exposure with feedback (REF)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Relevant exposure with no feedback (RENoF)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Irrelevant exposure with feedback (IEF)
Number of subjects: 45

Group type: COMPARATOR
Intervention: All groups (REF, RENoF, IEF)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Subjects' report of exposure treatment undertaken at home
Number of subjects: 45
Study: 7624106

Group type: EXPERIMENTAL
Intervention: 99Tcm-sestamibi (MIBI) injection for SPET imaging
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 27
Study: 2693076

Group type: EXPERIMENTAL
Intervention: Ethanolamine oleate (Et)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polidocanol (Pl)
Number of subjects: 50
Study: 627881

Group type: EXPERIMENTAL
Intervention: Low stimulus similarity task
Number of subjects: 30

Group type: COMPARATOR
Intervention: High stimulus similarity task
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Introverts
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Extroverts
Number of subjects: 30
Study: 31175001

Group type: EXPERIMENTAL
Intervention: Quizartinib (60 mg orally once daily, with a 30 mg lead-in)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice including low-dose cytarabine, mitoxantrone, etoposide, and others)
Number of subjects: 367
Study: 26692084

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (65 mg elemental magnesium) twice per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo twice per day
Number of subjects: 40
Study: 27429174

Group type: EXPERIMENTAL
Intervention: Exposure in vivo (EXP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pain-contingent treatment as usual (TAU)
Number of subjects: 46
Study: 23328738

Group type: EXPERIMENTAL
Intervention: Glucocorticoid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PRP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 21328522

Group type: EXPERIMENTAL
Intervention: ¹²³I-MIBG
Number of subjects: 350

Group type: COMPARATOR
Intervention: ¹³¹I-MIBG
Number of subjects: 350
Study: 19333746

Group type: EXPERIMENTAL
Intervention: Deliberation in simulated juries (4-7 persons)
Number of subjects: 0
Study: 17342074

Group type: EXPERIMENTAL
Intervention: High-energy yogurt preload beverage (YP: 500 ml, 1988 kJ for men; 375 ml, 1507 kJ for women)
Number of subjects: 54

Group type: COMPARATOR
Intervention: No preload (NP)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Active subjects
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sedentary subjects
Number of subjects: 54
Study: 15494230

Group type: EXPERIMENTAL
Intervention: Salivary amylase activity monitor using a testing-strip and optical analyzer measuring salivary amylase activity with a range of 0-200 kU/l within 150 s.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kraepelin psychodiagnostic test as a psychological stressor.
Number of subjects: 0
Study: 11341354

Group type: EXPERIMENTAL
Intervention: Levamisole (LMS) at four different dose levels over 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levamisole (LMS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levamisole (LMS) in vitro analysis
Number of subjects: 0
Study: 9004097

Group type: EXPERIMENTAL
Intervention: Non-malignant non-proteinuric normo-creatininaemic hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: African Americans with hypertension
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benign essential hypertension
Number of subjects: 0
Study: 1858444

Group type: EXPERIMENTAL
Intervention: Electronic pain diary
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional pain diary
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ibuprofen (NSAID)
Number of subjects: 20
Study: 6343149

Group type: EXPERIMENTAL
Intervention: Oral etretinate, 1 mg/kg b.w. for 8 weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31234587

Group type: EXPERIMENTAL
Intervention: Calcium-fortified, milk-derived protein matrix (MBPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (maltodextrin, CON)
Number of subjects: 0
Study: 28605730

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,200 mg/m2) and Vinorelbine (25 mg/m2) intravenously on days 1 and 8 every 3 weeks
Number of subjects: 42
Study: 27025864

Group type: EXPERIMENTAL
Intervention: Optical Coupling Control (OCC)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Blind coupling
Number of subjects: 336
Study: 24880692

Group type: EXPERIMENTAL
Intervention: Cigarette Cues
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alcohol Cues
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Cues
Number of subjects: 40
Study: 22996370

Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells (DC) loaded with antigens from tumor cells, injected subcutaneously in 500 µg of granulocyte‐macrophage colony stimulating factor, weekly for 3 weeks and then monthly for 5 months.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irradiated autologous proliferating tumor cells, injected subcutaneously in 500 µg of granulocyte‐macrophage colony stimulating factor, weekly for 3 weeks and then monthly for 5 months.
Number of subjects: 0
Study: 19440172

Group type: EXPERIMENTAL
Intervention: Super-absorbent polymer dressing
Number of subjects: 53
Study: 17486281

Group type: EXPERIMENTAL
Intervention: 20 mg of tadalafil on demand
Number of subjects: 1058

Group type: COMPARATOR
Intervention: 20 mg of tadalafil three times per week
Number of subjects: 1058
Study: 14734376

Group type: EXPERIMENTAL
Intervention: A&E physician present
Number of subjects: 124

Group type: COMPARATOR
Intervention: A&E physician absent
Number of subjects: 124
Study: 11989994

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 171

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 171
Study: 9801927

Group type: EXPERIMENTAL
Intervention: Low-dose heparin (12,500 U, subcutaneously daily) plus antianginal treatment
Number of subjects: 40
Study: 7621660

Group type: EXPERIMENTAL
Intervention: Training by a consumer on the second day of training
Number of subjects: 57

Group type: COMPARATOR
Intervention: Training by a nonconsumer on the second day of training
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Training by a consumer
Number of subjects: 57

Group type: COMPARATOR
Intervention: Training by a nonconsumer
Number of subjects: 57
Study: 2284220

Group type: EXPERIMENTAL
Intervention: Lornoxicam 12 mg daily
Number of subjects: 3
Study: 6108725

Group type: EXPERIMENTAL
Intervention: Prenalterol (1-10 microgram)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Terbutaline (2.5-250 ng)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: KWD 2131 (100 ng-2.5 microgram)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 10
Study: 31543351

Group type: EXPERIMENTAL
Intervention: Adjustable glasses
Number of subjects: 379

Group type: COMPARATOR
Intervention: Standard glasses
Number of subjects: 379
Study: 30192907

Group type: EXPERIMENTAL
Intervention: Contextually tailored activity suggestions (walking or antisedentary)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Any type of suggestion (walking or antisedentary)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Walking suggestion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Antisedentary suggestion
Number of subjects: 44
Study: 28747210

Group type: EXPERIMENTAL
Intervention: Souvenaid
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study: 25887358

Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 µg
Number of subjects: 142

Group type: COMPARATOR
Intervention: Liraglutide 1.2 mg
Number of subjects: 142

Group type: COMPARATOR
Intervention: Liraglutide 1.8 mg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 142

Group type: COMPARATOR
Intervention: Liraglutide 1.2 mg and 1.8 mg
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 142

Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 142
Study: 23578669

Group type: EXPERIMENTAL
Intervention: Preventive treatment (endovascular surgery, coiling, clipping) for UIAs larger than 5 mm
Number of subjects: 879

Group type: COMPARATOR
Intervention: Conservative management (observation) for UIAs
Number of subjects: 879
Study: 21274557

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil p.o.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg sildenafil p.o.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 μg iloprost inhalation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 19248129

Group type: EXPERIMENTAL
Intervention: Anakinra 50 mg
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Anakinra 150 mg
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 18246014

Group type: EXPERIMENTAL
Intervention: Titanium cages (TC)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Femoral ring allografts (FRA)
Number of subjects: 83
Study: 15499697

Group type: EXPERIMENTAL
Intervention: Adalimumab combined with methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 0
Study: 11274518

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9041991

Group type: EXPERIMENTAL
Intervention: IV IgG (Polyglobin, n = 14, total dosage: 18 mL/kg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: IV IgGMA (Pentaglobin, n = 13, total dosage: 15 mL/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both interventions (IgG and IgGMA)
Number of subjects: 29
Study: 7610025

Group type: EXPERIMENTAL
Intervention: Biplane rotational DSA
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional biplane DSA
Number of subjects: 33
Study: 3307795

Group type: EXPERIMENTAL
Intervention: Walking group
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 229
Study: 29156941

Group type: EXPERIMENTAL
Intervention: Dementia care management (DCM)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 317
Study: 27401564

Group type: EXPERIMENTAL
Intervention: Intravenous or oral fluconazole at 6 mg/kg of body weight twice weekly
Number of subjects: 141
Study: 25762749

Group type: EXPERIMENTAL
Intervention: Varenicline (VAR) tablets and placebo patches
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo tablets and nicotine patches
Number of subjects: 108
Study: 21610201

Group type: EXPERIMENTAL
Intervention: TAK-875 (25-800 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TAK-875 with high-fat meal
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19880786

Group type: EXPERIMENTAL
Intervention: Maintain testosterone and estradiol at eugonadal levels for young men (GnRH agonist + testosterone gel)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Block testosterone's conversion to estradiol (GnRH agonist + testosterone gel + aromatase inhibitor)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Induce hypogonadism (GnRH agonist alone)
Number of subjects: 4

Group type: COMPARATOR
Intervention: All placebo
Number of subjects: 4
Study: 17980667

Group type: EXPERIMENTAL
Intervention: Minocycline (up to 400 mg/day for 9 months)
Number of subjects: 412
Study: 15966755

Group type: EXPERIMENTAL
Intervention: Metformin XR 2000 mg once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Metformin IR 1000 mg twice daily
Number of subjects: 16
Study: 12483717

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of MRA
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10 mg/kg of MRA
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 5 mg/kg and 10 mg/kg of MRA
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All MRA cohorts
Number of subjects: 45
Study: 10488265

Group type: EXPERIMENTAL
Intervention: Intradermal bacteriostatic 0.9% sodium chloride containing the preservative benzyl alcohol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intradermal lidocaine hydrochloride 1%
Number of subjects: 40
Study: 8133085

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 1726
Study: 2777395

Group type: EXPERIMENTAL
Intervention: Gore-tex catheter
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oreopoulos catheter
Number of subjects: 20
Study: 1089399

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Imipramine or Amitriptyline
Number of subjects: 24
Study: 30784955

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 40
Study: 29947323

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient powders (MNP) and nutrition counselling
Number of subjects: 4356

Group type: COMPARATOR
Intervention: Nutrition counselling alone (Control)
Number of subjects: 4356
Study: 26685869

Group type: EXPERIMENTAL
Intervention: Angiotensin system inhibitors (ASIs) at baseline
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Sunitinib or pazopanib (control group)
Number of subjects: 1545